Plain-English translation of NCT06762769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —combined with two other medications called and —can prevent or slow down smouldering myeloma from developing into active multiple myeloma. Smouldering myeloma is an early form of blood cancer that grows slowly and often doesn't need treatment right away, but some patients have a higher risk of it progressing. The study will also look at how well patients tolerate the medication and how it affects their quality of life.
Right now, doctors usually just monitor patients with high-risk smouldering myeloma without treating them until it becomes active. This trial is testing whether treating patients earlier with this medication combination could prevent or delay that progression, potentially helping patients live longer without developing active cancer.
You likely qualify if…
You likely don't qualify if…
You would receive treatment for 2 years, divided into three stages over 26 cycles (each cycle is 4 weeks). In the first stage, you would receive injections under the skin using a small device, take as a capsule by mouth for 3 weeks of each cycle, and take as a tablet once a week. As you progress, the frequency of injections will decrease while you continue the other medications. You will attend regular clinic visits for check-ups, blood tests, and monitoring to see how well the treatment is working and how you are tolerating it.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United Kingdom